Orsini's Role in Acromegaly Treatment
Orsini has been selected as the specialty pharmacy partner for Crinetics Pharmaceuticals, Inc., to provide PALSONIFY™ (paltusotine), a groundbreaking therapy for treating acromegaly. This new oral therapy is designed for adults who either did not respond adequately to surgery or for whom surgical intervention is not viable.
The Significance of PALSONIFY™
PALSONIFY is the first FDA-approved once-daily treatment for acromegaly, a condition resulting from excess growth hormone caused by benign tumors in the pituitary gland. Individuals suffering from acromegaly often face physical changes, such as abnormal growth of the hands and feet, as well as serious health issues like joint pain, cardiovascular diseases, and metabolic disorders. If left untreated, acromegaly can lead to severe complications and a shortened lifespan.
Understanding Acromegaly
This condition typically manifests when a tumor in the pituitary gland causes an overproduction of growth hormone. The symptoms can significantly impact quality of life, making effective treatment crucial. PALSONIFY works by targeting specific receptors in the body to manage these hormone levels and alleviate symptoms.
Orsini's Commitment to Patient Care
Orsini's CEO, Brandon Tom, expressed excitement about this partnership, stating, "We’re honored to stand alongside Crinetics and the acromegaly community to provide access to PALSONIFY. For those living with acromegaly, every step toward effective treatment matters. Orsini is committed to walking that path with patients and healthcare providers, offering compassionate, meaningful support every step of the way." This commitment underscores their ongoing dedication to improving patient outcomes through access to innovative therapies.
About Orsini
Established in 1987, Orsini has built a reputation for providing comprehensive and compassionate care, particularly for patients with rare diseases and gene therapies. Their innovative approach supports patients and families in accessing vital treatments through partnerships with biopharma companies, healthcare providers, and payors.
Orsini offers integrated pharmacy solutions that encompass pharmacy distribution, patient services, clinical management, and home infusion services. Their high-touch care model includes experienced teams dedicated to personalizing patient care, ensuring that every individual receives the support they need—truly embodying the motto, "No Patient is Left Behind™." This emphasis on patient care has led to numerous accreditations from respected organizations.
Accreditations and Recognitions
Orsini's commitment to excellence is illustrated through its accreditations with the Accreditation Commission for Health Care (ACHC), The Joint Commission, URAC, and NABP. Recognized for their exemplary services, Orsini has received designations such as the Rare Disease Pharmacy Center of Excellence by URAC and Distinction in Rare Diseases and Orphan Drugs by ACHC. These accolades underscore their leadership and dedication to providing high-quality care in the rare disease sector.
Moving Forward
As Orsini joins forces with Crinetics to enhance patient access to PALSONIFY, the pharmacy aims to raise awareness and understanding of acromegaly. By offering innovative solutions and compassionate care, Orsini is poised to make a lasting impact on the lives of those affected by this condition.
Frequently Asked Questions
1. What is PALSONIFY™ used for?
PALSONIFY™ is an FDA-approved oral therapy for the treatment of acromegaly, specifically for patients who have not responded well to surgery.
2. How does PALSONIFY™ work?
PALSONIFY™ is a nonpeptide SST2 agonist that helps regulate growth hormone levels, thus alleviating the symptoms associated with acromegaly.
3. Why is Orsini an important partner for Crinetics?
Orsini specializes in rare disease pharmacy solutions, making it a valuable partner to enhance patient access to innovative treatments like PALSONIFY™.
4. What services does Orsini provide?
Orsini offers comprehensive pharmacy solutions, including pharmacy distribution, patient services, clinical management, and home infusion.
5. How long has Orsini been providing care?
Orsini has been dedicated to patient care since 1987, focusing on rare diseases and gene therapies to ensure comprehensive support for patients.
